These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1527229)

  • 1. Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations.
    Tacke U; Leinonen E; Lillsunde P; Seppälä T; Arvela P; Pelkonen O; Ylitalo P
    J Clin Psychopharmacol; 1992 Aug; 12(4):262-7. PubMed ID: 1527229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data.
    Balant-Gorgia AE; Balant LP; Garrone G
    Ther Drug Monit; 1989; 11(4):415-20. PubMed ID: 2741190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tricyclic antidepressants dosage and depressed elderly inpatients: a retrospective pharmaco-epidemiologic study].
    Ballon N; Siobud-Dorocant E; Even C; Slama F; Dardennes R
    Encephale; 2001; 27(4):373-6. PubMed ID: 11686060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring in depression.
    Radziwoń-Zaleska M; Matsumoto H; Skalski M; Androsiuk W; Dziklińska A; Kunicki PK
    Pol J Pharmacol; 2000; 52(4):255-66. PubMed ID: 11345481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].
    Jarema M
    Psychiatr Pol; 1995; 29(1):57-66. PubMed ID: 7878155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered distribution of the debrisoquine oxidative phenotypes in children with type 1 diabetes mellitus.
    Madácsy L; Barkai L; Sánta A; Krikovszky D
    Horm Res; 2004; 61(4):176-9. PubMed ID: 14726620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
    Sjöqvist F; Bertilsson L
    Prog Clin Biol Res; 1986; 214():169-88. PubMed ID: 3523507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
    Pollock BG; Perel JM; Altieri LP; Kirshner M; Fasiczka AL; Houck PR; Reynolds CF
    Psychopharmacol Bull; 1992; 28(2):163-8. PubMed ID: 1513919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA; Syrek M; Ryłko Z; Wójcikowski J
    Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
    Syvälahti EK; Lindberg R; Kallio J; De Vocht M
    Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.
    Bertilsson L; Aberg-Wistedt A; Gustafsson LL; Nordin C
    Ther Drug Monit; 1985; 7(4):478-80. PubMed ID: 4082245
    [No Abstract]   [Full Text] [Related]  

  • 19. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.
    Perault MC; Bouquet S; Bertschy G; Vandel S; Chakroun R; Guibert S; Vandel B
    Therapie; 1991; 46(1):1-3. PubMed ID: 2020918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
    Nikolov IG; Chernozemsky IN; Idle JR
    IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.